Drugs / NG004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06817577 | Dec 2024 → Sep 2026 overdue | spinal cord injury | NovaGo Therapeutics AG | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-02 | Neurimmune AG | Neurimmune co-leads USD 30 million Series B financing of NovaGo Therapeutics to advance anti-Nogo-A antibody NG004 for the treatment of acute spinal cord injury neurimmune.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06817577 ↗ |
| Modality | Monoclonal antibody | “Human Monoclonal Antibody NG004” NCT06817577 ↗ |
| Route | Intrathecal | “repeated intrathecal injections of NG004” NCT06817577 ↗ |